Application of Artificial intelligence (AI) in Pharmaceutical Industry: In-Depth Review
DOI:
https://doi.org/10.63682/jns.v14i26S.8441Keywords:
Artificial intelligence, Machine Learning, Deep Learning, Pharma Industry, Application of AI in Pharma, Drug Discovery, New Medicine Development, Drug FormulationAbstract
AI technologies are changing the pharmacy industry which includes the various processes of drug research, development, formulation, safety surveillance, and compliance to standards of law and ethics. This article explains in detail AI's impact on the Pharmacy industry. It includes the application of ML, DL, NLP, and computer vision, AI technologies on the different phases of life cycle of a drug. In drug discovery, AI boosts the determination of possible compounds with predictive modeling, virtual screening, SAR, and even de novo drug design. AI also enables the repurposing of existing drugs and aids in early-stage toxicity prediction. In formulation development, AI enhances the selection of excipients, design of dosage, and prediction of stability to be more precise and economical towards achieving patient-centered therapies.
AI powered pharmacovigilance technologies have improved the monitoring of ADRs through real-time analysis of EHRs data, social networks, and cases which increases patient safety and rational regulatory actions. AI also helps in the preparation and review of relevant papers, documentation, e-submission, and adhering to international standards in the case of regulatory affairs. The transformative impact of AI tools and technologies are on varied fields and industries. Though, the reasoning for slower integration across the board are ethical concerns, data privacy issues, high implementation costs, and even a lack of professionals who are trained in order to utilize AI’s capabilities.
This review is aimed AI's utilization in creating unique treatment strategies, managing rare health conditions, AI-enhanced clinical trial design and execution, AI-assisted manufacturing processes, and analysing mental health disorders. Considering continuous innovations alongside regulation framework support, it's now clear that AI will drastically change pharmaceutical research and healthcare services on a global scale
Downloads
Metrics
References
Mak KK and Pichika MR: Artificial intelligence in drug development: Present Status and future prospects. Drug Discov Today 2019; 24(3): 773-80.
https://www.scholarsresearchlibrary.com/articles/artificial-intelligence-in-pharmacy.pdf
Kawal F: A Tour to the World of Artificial Intelligence. Cybernomics 2020; 2(5): 33-35
Lopes V and Alexandre LA: An overview of blockchain integration with robotics and artificial intelligence. arXiv preprint arXiv:1810.00329, 2018
https://images.app.goo.gl/umcrTaYDZuHvXvCM9John Mc Caethy.
Bender, A., & Cortes-Ciriano, I. (2021). Artificial intelligence in drug discovery: what is realistic, what are illusions? Part 1: AI and data. Drug Discovery Today, 26(2), 511-524.
Mak, K.-K., & Pichika, M. R. (2019). Artificial intelligence in drug development: Present status and future prospects. Drug Discovery Today, 24(3), 773-780.
Pal R, Pandey P, Chawra HS, Singh RP. Niosomal as Potential Vesicular Drug Nano-carriers for the Treatment of Tuberculosis (TB). Nanoscience & Nanotechnology-Asia. 2025 Feb;15(1):E22106812323829.
Lee, S. L., O’Connor, T. F., Yang, X., & Cruz, C. N. (2020). Modernizing pharmaceutical manufacturing: AI and advanced analytics. Journal of Pharmaceutical Sciences, 109(10), 2757-2765.
Topol, E. J. (2019). High-performance medicine: The convergence of human and artificial intelligence. Nature Medicine, 25(1), 44-56.
Zhavoronkov, A. (2018). Artificial intelligence for drug discovery, biomarker development, and generation of novel chemistry. Molecular Pharmaceutics, 15(10), 4311-4313.
Fleming, N. (2018). How artificial intelligence is changing drug discovery. Nature, 557(7707), S55-S57.
Zhou, J., et al. (2020). Artificial Intelligence in Target Identification and Drug Discovery. Frontiers in Pharmacology, 11, 819.
A., & Cortes-Ciriano, I. (2021). Artificial intelligence in drug discovery: what is realistic, what are illusions? Drug Discovery Today, 26(3), 1040–1052.
Luechtefeld, T., et al. (2018). Machine learning of toxicological big data enables read-across structure activity relationships. Toxicological Sciences, 165(1), 198–212.
Vamathevan, J., et al. (2019). Applications of machine learning in drug discovery and development. Nature Reviews Drug Discovery, 18(6), 463–477.
Ashburn, T. T., & Thor, K. B. (2004). Drug repositioning: identifying and developing new uses for existing drugs. Nature Reviews Drug Discovery, 3(8), 673–683
Zhavoronkov, A., et al. (2019). Deep learning enables rapid identification of potent DDR1 kinase inhibitors. Nature Biotechnology, 37(9), 1038–1040.
Yin, J., Meng, L., Huang, W., & Zhang, W. (2020). Application of artificial intelligence in the pharmaceutical industry: challenges and opportunities. Frontiers in Pharmacology, 11, 1–11.
Mahmoud, D. B., & Roberts, C. J. (2021). Use of machine learning for pharmaceutical formulation: towards more intelligent drug product development. International Journal of Pharmaceutics: X, 3, 100090.
Pal R, Pandey P, Chawra HS, Khan Z. Nano Drug Delivery Carriers (Nanocarriers): A Promising Targeted Strategy in Tuberculosis and Pain Treatment. Pharmaceutical Nanotechnology. 2025 Mar 7.
Arshad, U., Pertinez, H., Box, H., & Liptrott, N. J. (2019). Artificial intelligence in formulation and stability prediction of biopharmaceuticals. Computational and Structural Biotechnology Journal, 17, 1609–1618.
Bate, A., & Dobson, R. (2019). Artificial intelligence in pharmacovigilance: Ready for prime time? Drug Safety, 42(6), 449–457.
Harrer, S., Shah, P., Antony, B., & Hu, J. (2019). Artificial Intelligence for Clinical Trial Design. Trends in Pharmacological Sciences, 40(8), 577–591.
Bate, A., & Evans, S. J. W. (2009). Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiology and Drug Safety, 18(6), 427–436.
Sarker, A., et al. (2015). Social media mining for toxicovigilance: Automatic monitoring of prescription medication abuse from Twitter. Drug Safety, 39(3), 231–240.
Harper, B. (2020). Automation in pharmacovigilance: The role of artificial intelligence in case processing. Pharmaceutical Technology Europe, 32(6), 12–15.
Trifiro, G., et al. (2019). Artificial intelligence in pharmacovigilance: State of the art and future perspectives. Drug Safety, 42(12), 1399–1410.
Chen, I., et al. (2020). Artificial intelligence in drug safety and benefit-risk assessment: Current status and future prospects. Clinical Pharmacology & Therapeutics, 107(4), 815–826.
International Council for Harmonisation (ICH). (2021). ICH Guideline E6(R3) on Good Clinical Practice.
Food and Drug Administration. (2021). Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD) Action Plan.
Gupta U, Kosey S, Pal R. Advancements in Nanotechnology-Based Targeted Drug Delivery Systems for Glioblastoma Chemotherapy: A Comprehensive Review. Journal of Drug Delivery Science and Technology. 2025 Jun 13:107181.
Jiang, F., Jiang, Y., Zhi, H., Dong, Y., Li, H., Ma, S., ... Wang, Y. (2017). Artificial intelligence in healthcare: past, present and future. Stroke and Vascular Neurology, 2(4), 230-243.
U.S. Food and Drug Administration. (2020). Electronic Submissions Gateway (ESG).
Jiang, F., Jiang, Y., Zhi, H., Dong, Y., Li, H., Ma, S., ... & Wang, Y. (2017). Artificial intelligence in healthcare: past, present and future. Stroke and Vascular Neurology, 2(4), 230–243.
Pal R, Pandey P, Nogai L, Anand A, Suthar P, SahdevKeskar M, Kumar V. The future perspectives and novel approach on gastro retentive drug delivery system (GRDDS) with currrent state. Journal of Population Therapeutics and Clinical Pharmacology. 2023 Sep 19;30(17):594-613.
Yu, K. H., Beam, A. L., & Kohane, I. S. (2018). Artificial intelligence in healthcare. Nature Biomedical Engineering, 2(10), 719–731.
Obermeyer, Z., & Emanuel, E. J. (2016). Predicting the future big data, machine learning, and clinical medicine. The New England Journal of Medicine, 375(13), 1216–1219.
Pal, Rahul & Kumar, Dinesh. (2025). Solid Lipid Nanoparticles (SLNPs): A State-of-the-Art Formulation Strategy and their Applications against Tuberculosis (TB) and Analgesic Effects. Nanoscience and Nanotechnology - Asia. 10.2174/0122106812379362250602075954.
Esteva, A., Robicquet, et.al. (2019). A guide to deep learning in healthcare. Nature Medicine, 25(1), 24–29
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
